Please use this identifier to cite or link to this item:
https://hdl.handle.net/2440/89270
Citations | ||
Scopus | Web of Science® | Altmetric |
---|---|---|
?
|
?
|
Type: | Journal article |
Title: | Can we accurately report PTEN status in advanced colorectal cancer? |
Author: | Hocking, C. Hardingham, J.E. Broadbridge, V. Wrin, J. Townsend, A.R. Tebbutt, N. Cooper, J. Ruszkiewicz, A. Lee, C. Price, T.J. |
Citation: | BMC Cancer, 2014; 14(1):128-1-128-7 |
Publisher: | BioMed Central |
Issue Date: | 2014 |
ISSN: | 1471-2407 1471-2407 |
Statement of Responsibility: | Christopher Hocking, Jennifer E Hardingham, Vy Broadbridge, Joe Wrin, Amanda R Townsend, Niall Tebbutt, John Cooper, Andrew Ruszkiewicz, Chee Lee, and Timothy J Price |
Abstract: | BACKGROUND: Loss of phosphatase and tensin homologue (PTEN) function evaluated by loss of PTEN protein expression on immunohistochemistry (IHC) has been reported as both prognostic in metastatic colorectal cancer and predictive of response to anti-EGFR monoclonal antibodies although results remain uncertain. Difficulties in the methodological assessment of PTEN are likely to be a major contributor to recent conflicting results. METHODS: We assessed loss of PTEN function in 51 colorectal cancer specimens using Taqman® copy number variation (CNV) and IHC. Two blinded pathologists performed independent IHC assessment on each specimen and inter-observer variability of IHC assessment and concordance of IHC versus Taqman® CNV was assessed. RESULTS: Concordance between pathologists (PTEN loss vs no loss) on IHC assessment was 37/51 (73%). In specimens with concordant IHC assessment, concordance between IHC and Taqman® copy number in PTEN loss assessment was 25/37 (68%). CONCLUSION: Assessment PTEN loss in colorectal cancer is limited by the inter-observer variability of IHC, and discordance of CNV with loss of protein expression. An understanding of the genetic mechanisms of PTEN loss and implementation of improved and standardized methodologies of PTEN assessment are required to clarify the role of PTEN as a biomarker in colorectal cancer. |
Keywords: | Humans Colorectal Neoplasms Tumor Markers, Biological Single-Blind Method Gene Expression Regulation, Neoplastic Sequence Deletion Observer Variation PTEN Phosphohydrolase |
Rights: | © 2014 Hocking et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. |
DOI: | 10.1186/1471-2407-14-128 |
Published version: | http://dx.doi.org/10.1186/1471-2407-14-128 |
Appears in Collections: | Aurora harvest 2 Medicine publications |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
hdl_89270.pdf | Published version | 664.87 kB | Adobe PDF | View/Open |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.